Showing 1671-1680 of 1732 results for "".
- Immediate Angiography May Improve Ischemic Stroke Treatment Outcomeshttps://practicalneurology.com/news/immediate-angiography-may-improve-ischemic-stroke-treatment-outcomes/2469535/A study in Spain presened at the International Stroke Conference held online March 17-19, 2021 showed that foregoing CT scan and proceeding immediately to angiography reduced treatment time and improved outcomes for people having ischemic strokes. Between October 2018 and November
- FDA Approves Ponesimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ponesimod-for-relapsing-multiple-sclerosis/2469532/The Food and Drug Administration (FDA) has approved ponesimod (Ponvory; Janssen, Titusville, NJ) for the treatment of relapsing forms of multiple sclerosis (MS). Ponesimode is an oral medication, taken once daily. In a randomized double-blind head-to-head phase 3 clinical trial (
- American Heart Association Releases Scientific Statement on Central Retinal Artery Occlusion, Calling it Eye Strokehttps://practicalneurology.com/news/american-heart-association-releases-scientific-statement-on-central-retinal-artery-occlusion-calling-it-eye-stroke/2469522/The American Heart Association and American Stroke Association have released a new scientific statement in Stroke, regarding central retinal artery occlusion (CRAO) as a form of ischemic stroke. The statemen
- FDA Grants Break Through and Orphan Drug Designations for Krabbe Disease Gene Therapyhttps://practicalneurology.com/news/fda-grants-break-through-and-orphan-drug-designations-for-krabbe-disease-gene-therapy/2469502/The Food and Drug Administration (FDA) announced that it has granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations for gene therapy (FBX-101, Forge Biologics, Inc.) to potentially treat Krabbe disease, a r
- New Genetic Tests Available for Hereditary Ataxiashttps://practicalneurology.com/news/new-genetic-tests-available-for-hereditary-ataxias/2469486/Several genetic tests, including repeat-expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxia have been newly made available by GeneDx (Gaithersberg, MD). The repeat-expansion analysis may be done concurrently with single nucleotide va
- Newly Launched Epilepsy Care Management Company, Nile, Aims to Create a Predictable Patient Journeyhttps://practicalneurology.com/news/newly-launched-epilepsy-care-management-company-nile-aims-to-create-a-predictable-patient-journey/2469474/UCB has announced the launch of a new company, Nile, that will offer a digital platform consisting of a patient app and a health care professional portal through which health care professionals and patients can interact. The formation of Nile is based on the observation that the intersections in
- FDA Okays Initiation of Phase 1/2 Trial of Gene Therapy for Krabbe Diseasehttps://practicalneurology.com/news/fda-okays-initiation-of-phase-12-trial-of-gene-therapy-for-krabbe-disease/2469466/The Food and Drug Administration (FDA) gave clearance for the first-in-human adeno-associated viral (AAV) gene therapy (FBX-101; Forge Biologics, Columbus, OH) for potential treatment of Krabbe disease. In preclinical trials in animal models, this gene therapy corrected the central and peripheral
- Remote Electric Neurostimulation Device Provides Pain Relief for Adolescents With Migrainehttps://practicalneurology.com/news/remote-electric-neurostimulation-device-provides-pain-relief-for-adolescents-with-migraine/2469464/In a study of therapeutic remote electric neuromodulation (REN) (Nerivio; Theranica, Netanya, Israel) for the acute treatment of migraine attacks in adolescents, freedom from pain was achieved by 35% of participants. In addition, 71% had pain relief at 2 hours. Pain relief and pain freedom were s
- Ghrelin Advances to a Phase 2 Trial for Concussion Treatmenthttps://practicalneurology.com/news/ghrelin-advances-to-a-phase-2-trial-for-concussion-treatment/2469406/A phase 2 clinical trial (NCT04558346) of ghrelin (OXE103; Oxeia Biopharmaceuticals, San Diego, CA) for treating concussions has been initiated. The compound being tested is a synthetic form of the end
- Diroximel Fumarate Treatment of Relapsing MS Has Improved Gastrointestinal Tolerability and Improved Quality of Lifehttps://practicalneurology.com/news/diroximel-fumarate-treatment-of-relapsing-ms-has-improved-gastrointestinal-tolerability-and-improved-quality-of-life/2469379/In EVOLVE-MS-2 (NCT03093324) trial of diroximel fumarate (Vumerity; Biogen, Cambridge, MA), recently approved for the treatment of relapsing forms of multiple sclerosis (MS), had significantly more gastrointestinal (GI) tolerability th